Enzo Biochem's Q3 Loss Widens on Revenue Decline

TL;DR

**Enzo Biochem is bleeding cash with no clear path to profitability, avoid this stock.**

AI Summary

ENZO BIOCHEM INC reported a net loss of $3.5 million for the quarter ended April 30, 2025, a significant increase from the $1.2 million net loss in the prior-year period. Revenue for the quarter was $8.2 million, down 15.5% from $9.7 million in the same quarter last year, primarily due to decreased sales in its clinical services segment. The company's gross profit margin declined to 35% from 42% year-over-year, impacted by higher cost of goods sold relative to revenue. Operating expenses remained substantial, with research and development expenses at $1.8 million and selling, general, and administrative expenses at $5.1 million for the quarter. Cash and cash equivalents decreased to $12.3 million as of April 30, 2025, from $15.8 million at July 31, 2024, indicating ongoing cash burn. The company continues to face challenges in its core business segments and is exploring strategic alternatives to enhance shareholder value.

Why It Matters

Enzo Biochem's widening net loss and declining revenue signal ongoing operational challenges, impacting investor confidence and potentially limiting future growth opportunities. The company's struggle to achieve profitability in a competitive biotech landscape could lead to further stock price volatility for investors. For employees, continued losses might raise concerns about job security and future investment in R&D. Customers could see reduced innovation or service offerings if financial pressures persist, while the broader market watches for signs of a turnaround in this niche biological products sector.

Risk Assessment

Risk Level: high — The company reported a net loss of $3.5 million for the quarter ended April 30, 2025, a substantial increase from the $1.2 million net loss in the prior-year period. Revenue declined by 15.5% to $8.2 million, and cash and cash equivalents decreased to $12.3 million from $15.8 million, indicating significant cash burn and a lack of sustainable profitability.

Analyst Insight

Investors should consider divesting from ENZO BIOCHEM INC given the consistent net losses, declining revenue, and ongoing cash burn. The company's financial performance suggests a high-risk investment with limited near-term upside potential.

Financial Highlights

debt To Equity

N/A

revenue

$8.2M

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$3.5M

eps

N/A

gross Margin

35%

cash Position

$12.3M

revenue Growth

-15.5%

Revenue Breakdown

Key Numbers

• $3.5M — Net Loss (Increased from $1.2M in prior year, indicating worsening profitability.)
• $8.2M — Revenue (Down 15.5% from $9.7M, reflecting declining sales.)
• 35% — Gross Profit Margin (Decreased from 42%, showing reduced efficiency in cost of goods sold.)
• $12.3M — Cash and Cash Equivalents (Decreased from $15.8M at July 31, 2024, highlighting ongoing cash burn.)
• 52,402,804 — Common Stock Outstanding (As of June 10, 2025, representing the total shares in circulation.)

Key Players & Entities

• ENZO BIOCHEM INC (company) — Registrant in 10-Q filing
• OTC Markets OTCQX (regulator) — Exchange where common stock is registered
• $3.5 million (dollar_amount) — Net loss for the quarter ended April 30, 2025
• $1.2 million (dollar_amount) — Net loss for the prior-year period
• $8.2 million (dollar_amount) — Revenue for the quarter ended April 30, 2025
• $9.7 million (dollar_amount) — Revenue for the prior-year period
• 15.5% (dollar_amount) — Percentage decrease in revenue year-over-year
• 35% (dollar_amount) — Gross profit margin for the quarter ended April 30, 2025
• 42% (dollar_amount) — Gross profit margin for the prior-year period
• $12.3 million (dollar_amount) — Cash and cash equivalents as of April 30, 2025

FAQ

Risk Factors

• Sustained Net Losses and Cash Burn [high — financial]: The company reported a net loss of $3.5 million for the quarter ended April 30, 2025, an increase from $1.2 million in the prior year. Cash and cash equivalents decreased to $12.3 million from $15.8 million at July 31, 2024, indicating continued negative cash flow and potential liquidity concerns.
• Declining Revenue and Gross Margins [high — operational]: Revenue fell 15.5% to $8.2 million, driven by lower sales in clinical services. The gross profit margin declined to 35% from 42% year-over-year, suggesting increased cost of goods sold relative to revenue and reduced operational efficiency.
• Exploration of Strategic Alternatives [medium — financial]: The company is actively exploring strategic alternatives to enhance shareholder value. This indicates potential uncertainty regarding the company's future direction and could lead to significant changes, including mergers, acquisitions, or divestitures.
• High Operating Expenses [medium — operational]: Operating expenses remain substantial, with R&D at $1.8 million and SG&A at $5.1 million for the quarter. These costs, coupled with declining revenue, contribute to the net loss and cash burn.

Industry Context

Enzo Biochem operates in the biotechnology and diagnostics sector, a highly competitive and research-intensive industry. Companies in this space often face challenges related to product development timelines, regulatory approvals, and market adoption. The sector is characterized by significant R&D investment and a need for continuous innovation to maintain a competitive edge.

Regulatory Implications

As a life sciences company, Enzo Biochem is subject to stringent regulatory oversight from bodies like the FDA. Compliance with evolving regulations for diagnostics and therapeutic products is critical. Any failure to meet these standards could result in significant penalties, product recalls, or delays in market access, impacting financial performance.

What Investors Should Do

1. Monitor cash burn and liquidity
2. Evaluate the progress of strategic alternatives
3. Analyze revenue drivers and cost management

Key Dates

• 2025-04-30: Quarterly Period End — Reporting period for the 10-Q filing, showing a net loss of $3.5 million and revenue of $8.2 million.
• 2025-06-16: 10-Q Filing Date — The company filed its quarterly report, providing updated financial and operational details.
• 2025-06-10: Common Stock Outstanding Date — As of this date, there were 52,402,804 shares of common stock outstanding.
• 2024-07-31: Prior Fiscal Year End — Reference point for cash and cash equivalents, which stood at $15.8 million prior to the current reporting period's decline.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document contains the detailed financial information for Enzo Biochem Inc. for the specified quarter.)

Gross Profit Margin

The percentage of revenue that exceeds the cost of goods sold (COGS). It indicates how efficiently a company manages its production costs. (Enzo Biochem's declining gross margin to 35% from 42% signals increased costs relative to revenue, impacting overall profitability.)

Cash and Cash Equivalents

Highly liquid short-term investments that can be readily converted into cash, representing a company's immediate liquidity. (The decrease to $12.3 million highlights the company's ongoing cash burn and potential need for financing.)

Operating Expenses

Costs incurred by a company in its normal business operations, excluding cost of goods sold. Includes R&D and SG&A. (Substantial operating expenses of $1.8M (R&D) and $5.1M (SG&A) contribute significantly to the company's net loss.)

Strategic Alternatives

A process where a company evaluates various options to maximize shareholder value, which can include selling the company, merging, or divesting assets. (Enzo Biochem's exploration of these alternatives suggests current business performance is unsatisfactory and may lead to significant corporate changes.)

Year-Over-Year Comparison

Compared to the prior-year period, Enzo Biochem Inc. has experienced a significant downturn. Revenue has decreased by 15.5% to $8.2 million, and the net loss has widened substantially from $1.2 million to $3.5 million. The gross profit margin has also deteriorated, falling from 42% to 35%, indicating less efficient cost management. Furthermore, the company's cash reserves have diminished, highlighting an ongoing cash burn that warrants investor attention.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on June 16, 2025 regarding ENZO BIOCHEM INC.

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR